ALSO NOTED: Varian buys IonSpec; China's Phynova debuts;and much more...

> Varian acquired IonSpec for $16 million. Varian gains the Fourier Transform mass spectrometry technology for its information-rich detection portfolio. Report

> China's Phynova surged on its public debut today. The drug developer has six drug candidates in the pipeline. Report

> Cell Genesys says that it expects to see the median survival time of patients rise in its second mid-stage trial of the cancer vaccine GVAX. Report

> Schering has exercised its option to purchase or lease the assets Chiron uses to manufacture Schering's MS drug Betaseron interferon beta-1b products. Report

> A category of popular drugs that includes Fosamax and Actonel can lead to bone death of the jaw. Report

> Norway's Algeta announced that its Phase II study of Alpharadin highlights its potential as a treatment for bone metastases in prostate cancer patients. Release

> Avalon Pharmaceuticals raised $7.25 million in a private placement. Release

> Peregrine Pharmaceuticals said that its therapy Tarvacin performed well in a Phase I trial. Release

> The FDA has approved Wockhardt's Ranitidine 75mg tablets as an over-the-counter therapy. Release

> Denmark's Genmab has reached its first milestone in its development deal with Serono. Release

And Finally... More than 60 bills have been filed by state lawmakers who either want to expand or restrict access to Plan B. Article